SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 24th, 2014 • Soon-Shiong Patrick • Services-commercial physical & biological research • California
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is dated this 14th day of December, 2014, by and between SORRENTO THERAPEUTICS, INC., a Delaware corporation (the “Company”), and CAMBRIDGE EQUITIES, LP (the “Purchaser”).
FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 24th, 2014 • Soon-Shiong Patrick • Services-commercial physical & biological research • California
This Amendment (the “Amendment”), made and entered into this 22nd day of December, 2014, by and between by Sorrento Therapeutics, Inc., a Delaware corporation (“Company”) and Cambridge Equities LP (the “Purchaser”), amends that certain securities purchase agreement, dated December 14, 2014, by and between the Company and the Purchaser (“Purchase Agreement”).
JOINT FILING AGREEMENTJoint Filing Agreement • December 24th, 2014 • Soon-Shiong Patrick • Services-commercial physical & biological research
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute but one agreement.
COMMON STOCK PURCHASE WARRANT SORRENTO THERAPEUTICS, INC.Common Stock Purchase Warrant • December 24th, 2014 • Soon-Shiong Patrick • Services-commercial physical & biological research
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Cambridge Equities, LP or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time and from time to time on or after December 22, 2014 (the “Initial Exercise Date”) and on or prior to the close of business on the three year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”), up to 1,724,138 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
